|
1
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Devi BC, Pisani P, Tang TS and Parkin DM:
High incidence of nasopharyngeal carcinoma in native people of
Sarawak, Borneo island. Cancer Epidemiol Biomarkers Prev.
13:482–486. 2004.PubMed/NCBI
|
|
3
|
Tao Q and Chang AT: Nasopharyngeal
carcinoma: Molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wee J: Nasopharyngeal cancer: A promising
future. Lancet Oncolo. 13:116–118. 2012. View Article : Google Scholar
|
|
5
|
Kinghorn AD, Pan L, Fletcher JN and Chai
H: The relevance of higher plants in lead compound discovery
programs. J Nat Prod. 74:1539–1555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pannel CM: Aglaia (Meliaceae). Tree flora
of Sabah and Sarawak. 6:Soepadmo E, Saw LG, Chung RCK and Kiew R:
(Kuala Lumpur). Forest Research Institute Malaysia. 27–107.
2007.
|
|
7
|
Ng BL, Omarzuki M, Lau GS, Pannel CM and
Yeo TC: A nucleotide signature for indentification of Aglaia
stellatopilosa pannel. Mol Biotechnol. 56:671–679. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cencic R, Carrier M, Galicia-Vázques G,
Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H,
Tremblay ML, et al: Antitumor activity and mechanism of action of
the cyclopenta[b]benzofuran, silvestrol. PLoS One. 4:e52232009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan L, Woodard JL, Lucas DM, Fuchs JR and
Kinghorn AD: Rocaglamide, silvestrol and structurally related
bioactive compounds from aglaia species. Nat Prod Rep. 31:924–939.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hwang BY, Su BN, Chai H, Mi Q, Kardono LB,
Afriastini JJ, Riswan S, Santarsiero BD, Mesecar AD, Wild R, et al:
Silvestrol and episilvestrol, potential anticancer rocaglate
derivatives from Aglaia silvestris. J Org Chem.
69:3350–3358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang DP, Ho JH, Poon YF, Chew EC, Saw D,
Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell
line (NPC/HK1) from a differentiated squamous carcinoma of the
nasopharynx. Int J Cancer. 26:127–132. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW,
Tsang YS, Wong N, Whitney BM and Lee JC: Nasopharyngeal carcinoma
cell line (C666-1) consistently harbouring Epstein-Barr virus. Int
J Cancer. 83:121–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan SY, Choy KW, Tsao SW, Tao Q, Tang T,
Chung GT and Lo KW: Authentication of nasopharyngeal carcinoma
tumor lines. Int J Cancer. 122:2169–2171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Daker M, Ahmad M and Khoo AS:
Quercetin-induced inhibition and synergistic activity with
cisplatin - a chemotherapeutic strategy for nasopharyngeal
carcinoma cells. Cancer Cell Int. 12:342012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daker M, Voon YL, Akowuah GA, Yam MF and
Mariam A: Inhibitory effects of Cinnamomum burmannii Blume
stem bark extract and trans-cinnamaldehyde on nasopharyngeal
carcinoma cells; synergism with cisplatin. Exp Ther Med.
5:1701–1709. 2013.PubMed/NCBI
|
|
17
|
Patton JT, Lustberg ME, Lozanski G, Garman
SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, et al:
The translation inhibitor silvestrol exhibits direct anti-tumor
activity while preserving innate and adaptive immunity against
EBV-driven lymphoproliferative disease. Oncotarget. 6:2693–2708.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patton JT, Lustberg ME, Garman SL,
Kinghorn AD, Pan L, Lucas DM, Grever MR and Baiocchi RA: Silvestrol
Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus
(EBV)-Associated Lymphomas While Sparing Innate and Antigen
Specific Adaptive Immunity. Presented at 53rd ASH Annual Meeting
and Exposition. (abstract 104). 2011.
|
|
19
|
Kim S, Hwang BY, Su BN, Chai H, Mi Q,
Kinghorn AD, Wild R and Swanson SM: Silvestrol, a potential
anticancer rocaglate derivative from Aglaia foveolata,
induces apoptosis in LNCaP cells through the
mitochondrial/apoptosome pathway without activation of executioner
caspase-3 or −7. Anticancer Res. 27:2175–2183. 2007.PubMed/NCBI
|
|
20
|
Lucas DM, Edwards RB, Lozanski G, West DA,
Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, et al:
The novel plant-derived agent silvestrol has B-cell selective
activity in chronic lymphocytic leukemia and acute lymphoblastic
leukemia in vitro and in vivo. Blood. 113:4656–4666. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mi Q, Kim S, Hwang BY, Su BN, Chai H,
Arbieva ZH, Kinghorn AD and Swanson SM: Silvestrol regulates G2/M
checkpoint genes independent of p53 activity. Anticancer Res.
26:3349–3356. 2006.PubMed/NCBI
|
|
22
|
Mi Q, Su BN, Chai H, Cordell GA,
Farnsworth NR, Kinghorn AD and Swanson SM: Rocaglaol induces
apoptosis and cell cycle arrest in LNCaP cells. Anticancer Res.
26:947–952. 2006.PubMed/NCBI
|
|
23
|
Alachkar H, Santhanam R, Harb JG, Lucas
DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti
D, et al: Silvestrol exhibits significant in vivo and in vitro
antileukemic activities and inhibits FLT3 and miR-155 expressions
in acute myeloid leukemia. J Hematol Oncol. 6:212013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boussemart L, Malka-Mahieu H, Girault I,
Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro
N, Thuaud F, et al: eIF4F is a nexus of resistance to anti-BRAF and
anti-MEK cancer therapies. Nature. 513:105–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bordeleau ME, Robert F, Gerard B,
Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco
JA Jr and Pelletier J: Therapeutic suppression of translation
initiation modulates chemosensitivity in a mouse lymphoma model. J
Clin Invest. 118:2651–2660. 2008.PubMed/NCBI
|
|
26
|
Cencic R, Carrier M, Trnkus A, Porco JA
Jr, Minden M and Pelletier J: Synergistic effect of inhibiting
translation initiation in combination with cytotoxic agents in
acute myelogenous leukemia cells. Leuk Res. 34:535–541. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kogure T, Kinghorn AD, Yan I, Bolon B,
Lucas DM, Grever MR and Patel T: Therapeutic potential of the
translation inhibitor silvestrol in hepatocellular cancer. PLoS
One. 8:e761362013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta SV, Sass EJ, Davis ME, Edwards RB,
Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, et
al: Resistance to the translation initiation inhibitor silvestrol
is mediated by ABCB1/P-glycoprotein overexpression in acute
lymphoblastic leukemia cells. AAPS J. 13:357–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saradhi UV, Gupta SV, Chiu M, Wang J, Ling
Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, et al:
Characterization of silvestrol pharmacokinetics in mice using
liquid chromatography-tandem mass spectrometry. AAPS J. 13:347–356.
2011. View Article : Google Scholar : PubMed/NCBI
|
